It was only recently that the multi-kinase inhibitor midostaurin in combination with chemotherapy and giltieritinib as monotherapy demonstrated clinical benefit in newly diagnosed FLT3-mutated AML and in relapsed/refractory disease respectively, leading to their FDA and EMA approval [13, 14]. This evidence concerns the gene FLT3 and acute myeloid leukemia.